Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial

Medical Oncology

Volumn 32, Issue 10, 2015, Pages

  Ochenduszko, Sebastian ^a   Puskulluoglu, Miroslawa ^a   Konopka, Kamil ^b   Fijorek, Kamil ^c   Urbanczyk, Katarzyna ^a   Budzynski, Andrzej ^a   Matlok, Maciej ^a   Lazar, Agata ^a   Sinczak Kuta, Anna ^a   Pedziwiatr, Michal ^a   Krzemieniecki, Krzysztof ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

^c CRACOW UNIVERSITY OF ECONOMICS   (Poland)

Author keywords

EOX; Gastric cancer; mDCF; Palliative chemotherapy; Safety; Toxicity

Indexed keywords

ANTIANEMIC AGENT; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; MEGESTROL ACETATE; OXALIPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; ANEMIA; ANOREXIA; ARTICLE; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; HAND FOOT SYNDROME; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH ADENOCARCINOMA; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; VOMITING; ADENOCARCINOMA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL JUNCTION; KAPLAN MEIER METHOD; MIDDLE AGED; PALLIATIVE THERAPY; SECONDARY; STOMACH NEOPLASMS;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CISPLATIN; DISEASE-FREE SURVIVAL; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84941360011     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0687-7     Document Type: Article

References (15)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37–41.
3. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 1995;71:58–91.
4. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjödén PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163–8.
5. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.
6. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006;24:4991–7.
8. Shah MA, Shibata S, Stoller R, Kemeny M, Ritch PS, Krishnamurthiet SS, et al. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). J Clin Oncol. 2010;28:15s,(suppl; abstr 4014).
9. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34:503–9.
10. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer: pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395–403.
11. Chau I, Ashley S, Cunningham D. Validation of the royal marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2. J Clin Oncol. 2009;. doi:10.1200/JCO.2009.22.0863.
12. Geynisman DM. Adherence to targeted oral anticancer medications. Discov Med. 2013;15:231–41.
13. Chen XL, Chen XZ, Yang C, Liao YB, Li H, Wang L, et al. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS ONE. 2013;. doi:10.1371/journal.pone.0060320.
14. Tetzlaff ED, Correa AM, Komaki R, Swisher SG, Maru D, Ross WA, et al. Significance of thromboembolic phenomena occurring before and during chemoradiotherapy for localized carcinoma of the esophagus and gastroesophageal junction. Dis Esophagus. 2008;21:575–81.
15. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632–4.